Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04269200
Title Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

endometrial carcinoma

Therapies

Durvalumab

Durvalumab + Olaparib

Carboplatin + Durvalumab + Paclitaxel

Carboplatin + Durvalumab + Olaparib + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.